Danina Fisher, Director at Hepion Pharmaceuticals, Inc. (HEPA), bought 200,000 shares at $0.05 ($10K) on 2026-09-29, disclosed to the SEC on 2026-10-02.
Director Danina Fisher purchased 200,000 shares at $0.05, marking the largest insider purchase in the company's history. This significant accumulation suggests insider confidence in the stock's potential recovery despite recent price stagnation.
HEPA is currently trading at $0.3181, flat over the last 30 days and sitting at its 52-week high of $0.3181. The stock is trading just 0.03% above its 52-week low of $0.318, indicating a consolidation phase near recent highs.
Insider cluster: This is the largest insider purchase ever recorded for Hepion; track this momentum as a potential signal. Short interest: With short interest at 4.1% of the float, a sustained buying interest from insiders could trigger a short squeeze.
Beta: The stock has a high beta of 1.758, meaning it is significantly more volatile than the market. Short interest: A short interest of 4.1% of the float exposes the stock to potential volatility if the buying pressure continues.
Nothing distinguishes this filing.